Introduction
============

Nasal septal deviation is one of the common diseases of otolaryngology that can seriously affect a patient's quality of life due to its effect on nasal function like headache, nasal obstruction, hyposmia, and runny nose.[@b1-tcrm-14-1871] Currently, treatment for nasal septum deviation involved septoplasty, which can sometimes result in postoperative complications such as bleeding, adhesion, and hematoma of the nasal septum. In order to reduce these postoperative complications and stabilize the nasal structure, it is conventional to pack high-expansion hemostatic sponge (Merocel, Medtronic Inc., Minneapolis, MN, USA) in nasal cavity for 48 hours.[@b2-tcrm-14-1871] However, the usage of nasal filling can cause serious pain to the patients for the duration of its application postoperation. Moreover, removing the stuffing afterwards tends to cause bleeding and further pain, which may further affect patients' postoperation quality of life.

Enhanced recovery after surgery (ERAS) was invented and developed by a group of academic surgeons in London in 2001.[@b3-tcrm-14-1871] It is a series of effective measures applied during preoperation, intraoperation, and postoperation to reduce surgical stress and complications, which can help speed up the postoperative rehabilitation, reduce pain, and shorten hospital stay, ultimately cutting down on the overall medical cost.[@b4-tcrm-14-1871] Other names are also used as fast-track surgery and enhanced recovery programs.[@b5-tcrm-14-1871] The ERAS measures include the following: 1) patient preoperative education; 2) more appropriate use of anesthesia techniques, surgical techniques, and analgesic therapy for reducing surgical stress and postoperative pain and complications; and 3) strengthening of postoperative rehabilitation therapy. At present, ERAS is predominantly applied for general surgery and bone surgery, which has shown remarkable results in postoperative care.[@b6-tcrm-14-1871],[@b7-tcrm-14-1871] In the field of otolaryngology, postoperative complications can severely impact patient quality of life due to the effects of respiratory symptoms that may affect day-to-day operations. Therefore, ERAS application to reduce postoperative pain, shorten hospital stay, and reduce hospitalization expenses may be beneficial in improving the overall effectiveness of surgery, postoperative, care and patient quality of life in the field. The aim of this study therefore was to assess improvements in postoperative care of otolaryngology surgeries following the first ERAS application in the field.

Materials and methods
=====================

Subjects
--------

From December 2017 to February 2018, 50 cases who underwent nasal septal correction in the Department of Otolaryngology of the Fifth Affiliated Hospital of Sun Yat-sen University were selected for further clinical observation and follow-up. The patients were divided into the control group (traditional group) and the ERAS group, with 25 cases in each group. The control group consisted of 13 males and 12 females with an average age of 35.6 years, while the ERAS group consisted of 15 males and 10 females with an average age of 37.2 years. The study was approved by the Ethical Committees of the Fifth Affiliated Hospitals of Sun Yat-sen University (Approved No. of ethic committee: 2017-K135-1), and written informed consent was obtained from each subject. The patient characteristics are listed in [Table 1](#t1-tcrm-14-1871){ref-type="table"}.

### Inclusion criteria

The inclusion criteria were as follows: 1) confirmed nasal septal deviation using endoscopy and computed tomography examination; 2) patients presented with different degrees of headache, nasal congestion, recurrent nasal bleeding, hyposmia, abscess, and other clinical symptoms; 3) no improvement of symptoms and assessment following conservative treatment.

### Exclusion criteria

Exclusion criteria were as follows: sinusitis, coagulant dysfunction; diabetics; mental abnormality; patients who are unfit or unsuitable for surgery; heart, kidney, and other important organ disorders; patients with respiratory diseases.

Procedure
---------

Patients followed the specific implementation measures and management of ERAS during hospital stay, as described in [Table 2](#t2-tcrm-14-1871){ref-type="table"}.

The intraoperative treatment of patients in ERAS group utilized trans-septal sutures for nasal septum, which can fix the nasal septum cartilage and repair torn mucosa. Furthermore, the nasal septal suture not only can prevent septal hemorrhage and hematoma, but also lessen patient pain and anxiety during nasal packing removal. The choice of the suture was made based on a randomized controlled clinical study by Awan and Iqbal,[@b8-tcrm-14-1871] which showed that nasal septal suture was better than nasal filling in reducing postoperative pain, where there was no difference in the incidence of postoperative complications. Moreover, Hari et al[@b9-tcrm-14-1871] also applied uninterrupted suture technique instead of interrupted suture technique to deal with the septum, which can be better protect torn local mucosa and prevent the postoperative complications such as bleeding and septal hematoma.

By referring to Hari et al's[@b9-tcrm-14-1871] nasal septum suture method, the operation was performed with a 0° nasal endoscope, and vircryl 4-0 absorbable angle needle for suture. The first needle is inserted from the left side of the nasal septum anterior to the middle turbinate to the right nasal cavity. Then, the needle is inserted from the back and downward of right nasal septum to the left nasal cavity. After that, the "Z" zigzag pattern is used in this method to make an uninterrupted suture. Finally, the septum incision was closed by tying the fixed suture.

Assessment
----------

The assessment of ERAS effect is performed based on length of stay (days), operating time (minutes), bleeding volume (mL), total cost (Dollars), complications, visual analog symptom score (VAS) which includes nasal obstruction, sleep disturbance, head facial pain (scored on a scale of 0--10 where patients mark their severity of the symptoms on the reverse side of scale and the physician evaluates the score indicated by the patients[@b10-tcrm-14-1871]), and perioperative anxiety evaluation on a self-rating anxiety scale (SAS; the boundary value of SAS standard score is 50, a score of 50--59 is for mild anxiety, 60--69 is for moderate anxiety, and 70 is for severe anxiety[@b11-tcrm-14-1871]).

Hospital discharge criteria
---------------------------

A VAS of each index (nasal obstruction, sleep disturbance, head facial pain) at \<3 was set as a criteria for discharge.

Statistical method
------------------

All data were assessed using SPSS 22.0 statistical software (IBM Corporation, Armonk, NY, USA). Measurement data (including average age, postoperative such confinement and VAS score) used x±s. Comparison between the 2 groups used independent-sample *t*-test. N (%) was used for enumeration data (including gender, disease, and postoperative complications), and Fisher's exact test method or χ^2^ test was used between the 2 groups. *P*\<0.05 indicates that the difference is statistically significant.

Results
=======

[Table 3](#t3-tcrm-14-1871){ref-type="table"} and [Figures 1](#f1-tcrm-14-1871){ref-type="fig"} and [2](#f2-tcrm-14-1871){ref-type="fig"} show that there was no significant difference in the operation time and blood volume between the ERAS group and the control group (traditional surgical procedures). Additionally, none of the 50 patients in the 2 groups had postoperative complication. However, length of stay and total cost were significantly lower in the ERAS group than in the control group. The patients in the control group (traditional surgical procedures) generally required 5.8 days of hospitalization; while with ERAS application, the time was significantly reduced to 4.4 days. The reduction can greatly reduce hospital stay, which increases the utilization rate of beds. In terms of total hospital expenses, the application of ERAS (1,252.5 Dollars) also cost significantly less than traditional nasal septal surgery (1,333.7 Dollars), which reduces the financial burden of patients.

The preoperative anxiety in ERAS group (SAS 35.4±6.2) was significantly lower than that of the traditional group (SAS 43.6±8.6), as shown in [Table 4](#t4-tcrm-14-1871){ref-type="table"} and [Figure 3](#f3-tcrm-14-1871){ref-type="fig"}. This was due to the ERAS group having sufficient preoperative physician--patient communication which detailed the treatment procedures. The level of anxiety in ERAS group (SAS 31.6±5.4) also remained lower compared to the traditional group (SAS 38.1±10.4) 3 days postsurgery, possibly due to the ERAS group not using nasal cavity filling, which prevented additional postoperative pain from the nasal filling removal. Furthermore, the nasal cavity was more ventilated after surgery and sleep was more restful, and the appropriate use of painkillers during the perioperative period helped prevent mood swings that arise from postoperative pain. The anxiety index of the 2 groups showed no significant difference on the seventh day postoperation, indicating that the therapeutic effect of the 2 groups is comparable, and the application of ERAS does not affect the curative effect.

[Table 5](#t5-tcrm-14-1871){ref-type="table"} and [Figure 4](#f4-tcrm-14-1871){ref-type="fig"} show that nasal congestion situation of patients with nasal septum is not only alleviated in the ERAS group (VAS preoperative 7.2, the first day after operation 5.1), but also met discharge standards by the third day postoperation (VAS 2.8). On the other hand, the congestion situation on the first (VAS 9.2) and second (VAS 9.0) day postoperation was more serious than preoperation (VAS 6.9) in the traditional group. This was due to patients only able to breathe through the mouth because of the application of postoperative nasal cavity filling, increasing the tendency to have dry or sore throat and headache. The nasal congestion in the traditional group eased starting from the third day postoperation and reached the discharge standard on the fifth day postoperation (VAS 3.0) upon removal of nasal packing.

There was little impact on sleep in the ERAS group after operation. The VAS of sleep disturbance was 3.1 on the first day and 2.6 on the second day postoperation. Therefore, the application of ERAS ensured patients to get good rest, improved the clinic experience, and promoted postoperative recovery. In contrast, sleep was highly affected in the traditional group, with a VAS of 6.7 on the first day postoperation due to the nasal filling. The VAS score was at 6.5 on the first day and dropped to 2.8 on the fourth day postoperation.

The ERAS group had an even greater improvement in terms of head and/or facial pain. The VAS score of pain was 3.5 on the first day postoperation, while the control group scored 6.5. That meant the pain of the control group was almost twice that of the ERAS group. Furthermore, the pain continued to decrease in the ERAS group on the second day postoperation, which met the discharge standard with a VAS of 2.4, possibly aided by the appropriate use of painkillers. On the other hand, the pain in the traditional group showed almost no significant change on the second day postoperation (VAS 6.0), which was largely related to the pain caused by the nasal filling. The traditional group's pain VAS score only began to reduce on the third (3.9), fourth (3.1), and fifth (2.5) days postsurgery after the removal of the nasal packing.

Discussion
==========

Septal deviation is a common and multifactorial clinical symptom that has a significant impact on the quality of life through its many complications that arise as the disease progresses.[@b12-tcrm-14-1871] This is usually caused by a trauma during the growth period and genetic factors.[@b13-tcrm-14-1871] The most common treatment for nasal septum deviation is through traditional nasal endoscopic septoplasty, which can relieve nasal congestion and hemorrhage, but has disadvantages including postoperative pain and high cost.[@b14-tcrm-14-1871] In our study, ERAS was capable of preventing these problems while improving the patient quality of life postsurgery.

In traditional nasal endoscopic septoplasty, nasal cavity filling was always applied postoperatively to prevent postoperative bleeding. However, the application of nasal filling is highly dependent on physician experience to prevent bleeding and hematoma while stabilizing the septum, not to mention that it can be the source of mucosa damage and can increase pain, cost, and complications.[@b15-tcrm-14-1871] Moreover, traditional surgical procedures caused patients to be more prone to anxiety and poor medical experience before surgery ([Figure 3](#f3-tcrm-14-1871){ref-type="fig"}). To address this, the systemic therapy of ERAS which includes the use of intraoperative trans-septal suture supplemented with pain control removed the need for nasal filling and avoided the tampering of the common meatus. The most commonly used material in septal suture surgery is the vircryl 4-0 line, which is a nontoxic and nonirritant material that can be absorbed. The intraoperative treatment of patients in the ERAS group utilized trans-septal sutures for nasal septum, which can fix the nasal septum cartilage and repair torn mucosa. Furthermore, the nasal septal suture not only can prevent septal hemorrhage and hematoma but also lessen patient pain and anxiety during nasal packing removal. The choice of the suture was made based on a randomized controlled clinical study by Awan and Iqbal,[@b8-tcrm-14-1871] which showed that nasal septal suture was better than nasal filling in reducing postoperative pain, but there was no difference in the incidence of postoperative complications. Moreover, Hari et al[@b9-tcrm-14-1871] also applied uninterrupted suture technique instead of interrupted suture technique to deal with the septum, which can better protect torn local mucosa and prevent postoperative complications such as bleeding and septal hematoma. Postoperative patients can avoid the direct nasal pain source caused by the filling, and other indirect postoperative discomfort such as dry mouth, inappetence, and difficulty sleeping caused by mouth breathing. Additionally, eliminating the use of nasal filling can also prevent the pain, bleeding, and nasal mucosa damage from its removal 2 days postoperation. The prevention and pain management postoperation through the application of ERAS can thus relieve postoperative patient anxiety and improve overall postoperative experience ([Figures 3](#f3-tcrm-14-1871){ref-type="fig"}[](#f4-tcrm-14-1871){ref-type="fig"}[](#f5-tcrm-14-1871){ref-type="fig"}--[6](#f6-tcrm-14-1871){ref-type="fig"}).

With the modernization of medical practice comes the rising cost in medical expenses. As such, our study showed that the application of ERAS can shorten the time of hospitalization and therefore reduce the total cost of hospitalization and medical procedures. The finding on ERAS application is in line with the current health care state where medical resources are barely meeting the rising demands and a new health care plan need to be devised to control medical and medical operations cost while improving patient experience and their quality of life. Additionally, application of ERAS can improve physician--patient communications to improve compliance and reduce other negative impacts in the treatment processes, which also indirectly increase patient satisfaction as well as confidence in the health care scene. Therefore, the first application of ERAS in the field of otolaryngology yielded a promising outcome so that more large-scale implementation can happen in the future.

Conclusion
==========

Our study indicated ERAS application can reduce hospital charges and postoperative pain in septoplasty, thereby improving patient quality of life and hospital expenses at the same time.
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![The mean hospital stay of patients in the ERAS group was shorter than the control group.\
**Abbreviation:** ERAS, enhanced recovery after surgery.](tcrm-14-1871Fig1){#f1-tcrm-14-1871}

![The mean total cost in ERAS group was lower than the control group.\
**Abbreviation:** ERAS, enhanced recovery after surgery.](tcrm-14-1871Fig2){#f2-tcrm-14-1871}

![The SAS score in ERAS group was lower than the control group in preoperation and 3 days postoperation, but showed no significant difference compared with those of 7 days postoperation.\
**Abbreviations:** ERAS, enhanced recovery after surgery; SAS, Self-Rating Anxiety Scale.](tcrm-14-1871Fig3){#f3-tcrm-14-1871}

![The VAS of nasal obstruction in ERAS group was lower than the control group.\
**Abbreviations:** ERAS, enhanced recovery after surgery; VAS, visual analog symptom score.](tcrm-14-1871Fig4){#f4-tcrm-14-1871}

![The VAS of sleep disturbance in ERAS group was lower than the control group.\
**Abbreviations:** ERAS, enhanced recovery after surgery; VAS, visual analog symptom score.](tcrm-14-1871Fig5){#f5-tcrm-14-1871}

![The VAS of head facial pain in ERAS group was lower than the control group.\
**Abbreviations:** ERAS, enhanced recovery after surgery; VAS, visual analog symptom score.](tcrm-14-1871Fig6){#f6-tcrm-14-1871}

###### 

Patient characteristics

                            ERAS group (n=25)   Control group (n=25)
  ------------------------- ------------------- ----------------------
  Age, mean±SD, (years)     37.2±10.5           35.6±13.7
  Sex (female:male)         15:10               13:12
  BMI, mean±SD, (kg/m^2^)   21.1±2.9            22.7±2.0

**Abbreviations:** BMI, body mass index; ERAS, enhanced recovery after surgery.

###### 

Concrete implementation measures of ERAS

                                                                ERAS group                                      Control group
  ------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------
  Preoperative                                                                                                  
   ERAS education[a](#tfn2-tcrm-14-1871){ref-type="table-fn"}   Done                                            None
   Nothing Per os[b](#tfn3-tcrm-14-1871){ref-type="table-fn"}   Fasting 6 hours, fasting water 2 hours          8 hours
  Intraoperative                                                                                                
   Anesthesia scheme                                            Local anesthesia and GA                         Tracheal intubationa and GA[c](#tfn4-tcrm-14-1871){ref-type="table-fn"}
   Temperature control                                          Supervise and avoid hypothermia                 Common processing
   Liquid control                                               Recude the infusion                             Common processing
   Cavity processing                                            Nasal septum stitching, without nasal filling   Expansion sponge
  Postoperative                                                                                                 
   Common analgesia                                             Oral NSAID                                      None
   Early eating and drinking                                    2 hours after surgery                           None
   Early off-bed activity                                       2 hours after surgery                           None
   Remove nasal pecking                                         None                                            48 hours after surgery

**Notes:**

ERAS education: explaining of ERAS process and signing of informed notification.

Nothing Per os: fasting for solids and liquids.

GA: common processing.

**Abbreviations:** ERAS, enhanced recovery after surgery; GA, general anesthesia; NSAID, nonteroidal anti-inflammatory drug.

###### 

Analysis of control group and ERAS group

                                       ERAS group     Control group   *P*-value
  ------------------------------------ -------------- --------------- -----------
  Length of stay, mean±SD, (days)      4.4±0.5        5.8±0.8         \<0.001
  Operating time, mean±SD, (minutes)   33.4±4.1       30.7±5.1        0.103
  Bleeding volume, mean±SD, (mL)       6.2±2.1        6.6±2.3         0.161
  Total cost, mean±SD, (Dollars)       1,252.5±21.0   1,333.7±38.1    \<0.001
  Complications                        0              0               --

**Notes:** Statistically significant (*P*\<0.05); -- indicates that not able to compare *P* values between the two groups.

**Abbreviation:** ERAS, enhanced recovery after surgery.

###### 

SAS score preoperation and after operation

  SAS score      ERAS group   Control group   *P*-value
  -------------- ------------ --------------- -----------
  Preoperation   35.4±6.2     43.6±8.6        \<0.001
  3 days         31.6±5.4     38.1±10.4       0.034
  7 days         29.2±5.0     31.2±9.3        0.305

**Notes:** Statistically significant (*P*\<0.05). Data presented as mean±SD.

**Abbreviation:** SAS, Self-Rating Anxiety Scale.

###### 

VAS score preoperation and after operation

  VAS                 Preoperation   1 day                                                   2 days                                                  3 days                                                  4 days    5 days
  ------------------- -------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- --------- ---------
  Nasal obstruction                                                                                                                                                                                                    
   ERAS group         7.2±1.5        5.1±1.2[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}   3.5±1.2[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}   2.8±0.9[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}             
   Control group      6.9±1.5        9.2±0.7                                                 9.0±0.8                                                 5.5±1.7                                                 4.1±1.2   3.0±1.1
  Sleep disturbance                                                                                                                                                                                                    
   ERAS group         1.6±1.2        3.1±1.4[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}   2.6±1.3[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}                                                                     
   Control group      1.9±1.5        6.7±2.4                                                 6.5±2.3                                                 4.3±1.0                                                 2.8±1.1   
  Head facial pain                                                                                                                                                                                                     
   ERAS group         0              3.5±1.3[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}   2.4±0.9[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}   2.0±0.8[\*](#tfn11-tcrm-14-1871){ref-type="table-fn"}             
   Control group      0              6.5±2.2                                                 6.0±2.0                                                 3.9±0.9                                                 3.1±0.9   2.5±0.6

**Notes:** Data presented as mean±SD.

Statistical differences between ERAS group and Control group (*P*\<0.05).

**Abbreviations:** ERAS, enhanced recovery after surgery; VAS, visual analog symptom score.
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